Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-30 @ 1:24 AM
Study NCT ID:
NCT07452757
Status:
COMPLETED
Last Update Posted:
2026-03-12
First Post:
2026-01-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
To Evaluate Efficacy and Safety of Proprietary Healthy Diet Combinations for Weight Management in Overweight Volunteers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D050177', 'term': 'Overweight'}], 'ancestors': [{'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D001835', 'term': 'Body Weight'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 140}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2023-11-15', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2026-01', 'completionDateStruct': {'date': '2024-05-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2026-03-10', 'studyFirstSubmitDate': '2026-01-30', 'studyFirstSubmitQcDate': '2026-02-27', 'lastUpdatePostDateStruct': {'date': '2026-03-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-03-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-05-13', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in Body Weight', 'timeFrame': 'Baseline (Day 1) to end of intensive phase (Day 30)', 'description': 'To assess the number and percentage of subjects demonstrating a reduction in body weight from baseline to the end of the intensive phase across intervention and control arms.'}], 'secondaryOutcomes': [{'measure': 'Change in BMI During Maintenance Phase', 'timeFrame': 'Baseline (Day 1) to end of study (Day 90)', 'description': 'To assess the number and percentage of subjects demonstrating a reduction in BMI from baseline to the end of the maintenance phase, and the proportion of subjects maintaining weight loss achieved during the intensive phase.'}, {'measure': 'Change in Body Fat Percentage', 'timeFrame': 'Baseline (Day 1) to end of study (Day 90)', 'description': 'To evaluate the change in body fat percentage from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.'}, {'measure': 'Change in Waist Circumference', 'timeFrame': 'Baseline (Day 1) to end of study (Day 90)', 'description': 'To assess the change in waist circumference from baseline to the end of the study and to compare the mean change between intervention and control arms.'}, {'measure': 'Change in Total Cholesterol', 'timeFrame': 'Baseline (Day 1) to end of study (Day 90)', 'description': 'To evaluate the change in total cholesterol levels from baseline to the end of the study and to compare the mean change between intervention and control arms.'}, {'measure': 'Change in Quality of Life', 'timeFrame': 'Baseline (Day 1) to end of study (Day 90)', 'description': 'Change from baseline in quality of life assessed using the World Health Organization Quality of Life - Brief Version (WHOQOL-BREF) questionnaire from baseline to the end of the study. The WHOQOL-BREF is a validated 26-item questionnaire that assesses four domains: physical health, psychological health, social relationships, and environment. Domain scores are transformed to a 0-100 scale, where higher scores indicate better quality of life.'}, {'measure': 'Incidence of Adverse Events', 'timeFrame': 'From baseline (Day 1) to end of study (Day 90)', 'description': 'To assess the incidence, severity, and relationship of adverse events reported during the study period across all study arms.'}, {'measure': 'Change in Muscle Mass', 'timeFrame': 'Baseline (Day 1) to End of Study (Day 90)', 'description': 'To evaluate the change in muscle mass from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.'}, {'measure': 'Change in Fat-Free Mass', 'timeFrame': 'Baseline (Day 1) to End of Study (Day 90)', 'description': 'To evaluate the change in fat-free mass from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.'}, {'measure': 'Change in Visceral Fat Level', 'timeFrame': 'Baseline (Day 1) to End of Study (Day 90)', 'description': 'To evaluate the change in visceral fat level from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.'}, {'measure': 'Change in Waist-to-Hip Ratio', 'timeFrame': 'Baseline (Day 1) to End of Study (Day 90)', 'description': 'To assess the change in waist-to-hip ratio from baseline to the end of the study and to compare the mean change between intervention and control arms.'}, {'measure': 'Change in Skinfold Thickness', 'timeFrame': 'Baseline (Day 1) to End of Study (Day 90)', 'description': 'To assess the change in skinfold thickness from baseline to the end of the study and to compare the mean change between intervention and control arms.'}, {'measure': 'Change in Triglycerides', 'timeFrame': 'Baseline (Day 1) to End of Study (Day 90)', 'description': 'To evaluate the change in triglyceride levels from baseline to the end of the study and to compare the mean change between intervention and control arms.'}, {'measure': 'Change in High-Density Lipoprotein (HDL) Cholesterol', 'timeFrame': 'Baseline (Day 1) to End of Study (Day 90)', 'description': 'To evaluate the change in HDL cholesterol levels from baseline to the end of the study and to compare the mean change between intervention and control arms.'}, {'measure': 'Change in Low-Density Lipoprotein (LDL) Cholesterol', 'timeFrame': 'Baseline (Day 1) to End of Study (Day 90)', 'description': 'To evaluate the change in LDL cholesterol levels from baseline to the end of the study and to compare the mean change between intervention and control arms.'}, {'measure': 'Change in Fasting Blood Glucose', 'timeFrame': 'Baseline (Day 1) to End of Study (Day 90)', 'description': 'To evaluate the change in fasting blood glucose levels from baseline to the end of the study and to compare the mean change between intervention and control arms.'}, {'measure': 'Change in Glycated Hemoglobin (HbA1c)', 'timeFrame': 'Baseline (Day 1) to End of Study (Day 90)', 'description': 'To evaluate the change in HbA1c levels from baseline to the end of the study and to compare the mean change between intervention and control arms.'}, {'measure': 'Change in Serum Insulin', 'timeFrame': 'Baseline (Day 1) to End of Study (Day 90)', 'description': 'To evaluate the change in fasting serum insulin levels from baseline to the end of the study and to compare the mean change between intervention and control arms.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Weight management programme'], 'conditions': ['Overweight (BMI > 25)']}, 'descriptionModule': {'briefSummary': 'This is an open-label, four-arm, randomized, controlled clinical study designed to evaluate the efficacy and safety of a structured Weight Management Program (WMP) in overweight and obese adults with a body mass index (BMI) ≥ 23 kg/m² (Asian Indian ethnicity cut-off). A total of 140 subjects will be enrolled and randomized equally into four arms: one control arm and three intervention arms with varying levels of nutritional intervention.\n\nThe Weight Management Program comprises three sequential phases: a pre-engagement gut-reset phase (10 days), an intensive intervention phase (30 days), and a maintenance phase (60 days). The intervention arms will receive combinations of meal replacements, protein supplements, fiber supplements, probiotics, and multivitamin-multimineral supplements, along with nutritional and behavioral counseling, calorie-deficit diet plans, and prescribed physical activity. The control arm will follow a free-living lifestyle without intervention.\n\nThe primary efficacy outcome is the proportion of subjects demonstrating a reduction in body weight and/or BMI from baseline to the end of the intensive phase. Secondary outcomes include changes in body weight and BMI at the end of the maintenance phase, maintenance of weight loss, changes in body composition, waist circumference, waist-hip ratio, lipid profile, metabolic parameters, physical activity, quality of life, and safety outcomes including adverse events.\n\nThe study aims to generate evidence on the effectiveness and safety of a holistic, lifestyle-based weight management program incorporating nutritional supplementation, dietary modification, physical activity, and behavioral support in overweight and obese individuals.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '20 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* \\- Male and female subjects age between 20 to 45 years\n* Non-pregnant and non-lactating\n* Body Mass Index (kg/m2)- ≥ 23 (considered overweight/obese as per the ethnicity cut off values for Asian Indians)\n* Following stable eating habits\n* Not on any medication that can affect Lipid profile, body composition or weight\n* Nonalcoholic and non- smoker\n* Subjects who are willing to sign the informed consent and comply with study requirement of meal replacements strictly\n* Women in the reproductive age group- should be agreeing to follow standard contraceptive measures\n* Individuals who are seriously motivated to lose weight and willing to be part of any one of the interventions where Protein drink with buttermilk, skimmed milk or water OR 1 Meal replacement OR 2 Meal replacement would be given.\n\nExclusion Criteria:\n\n* \\- On medication/ HRT (Hormone Replacement Therapy)\n* Suffering from endocrine hypothalamic- pituitary disease, women with PCOS, adrenal disorder, hypothyroidism,\n* Subjects with Diabetes type 1 or 2 to be excluded\n* Women in the reproductive age group not willing to use standard contraceptive measures.\n* Other conditions like CKD, stones, liver dysfunction (with elevated enzyme levels), history of cancer, eating disorders, chronic gastrointestinal disorders (IBD or celiac), metabolic disorders like hypertension, CVDs- that might impair the outcomes\n* Malignancy which is currently active or in remission for less than five years after last treatment\n* Unstable weight (± 5 % fluctuation in their body weight for past 8-weeks at study entry)\n* Have undergone gastroplasty or weight reducing surgery\n* Subjects who have participated in another clinical study within the past 30 days prior to screening or are likely to simultaneously participate in another clinical study.\n* Practicing any structured commercial weight management program/ intermittent fasting or any diet regime in the last 30 days prior to screening.\n* Patients who are doubtful to comply with study procedures for mental, psychological or social reasons.'}, 'identificationModule': {'nctId': 'NCT07452757', 'briefTitle': 'To Evaluate Efficacy and Safety of Proprietary Healthy Diet Combinations for Weight Management in Overweight Volunteers', 'organization': {'class': 'INDUSTRY', 'fullName': 'Bioagile Therapeutics Pvt. Ltd.'}, 'officialTitle': 'To Evaluate the Efficacy and Safety of Weight Management Program in Overweight/Obese Individuals: A 4 Arm Open Label Randomized Controlled Clinical Study', 'orgStudyIdInfo': {'id': 'AMW/ CTP/WMP/07-2022'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'NO_INTERVENTION', 'label': 'Arm I (Control group)'}, {'type': 'EXPERIMENTAL', 'label': 'Arm II (PRP-02 before all the meals)', 'interventionNames': ['Dietary Supplement: Arm II']}, {'type': 'EXPERIMENTAL', 'label': 'Arm III (1 meal replacement)', 'interventionNames': ['Dietary Supplement: Arm III']}, {'type': 'EXPERIMENTAL', 'label': 'Arm IV (2 Meal replacement)', 'interventionNames': ['Dietary Supplement: Arm IV']}], 'interventions': [{'name': 'Arm II', 'type': 'DIETARY_SUPPLEMENT', 'description': 'I. Investigational Product Morning- PRP-02 (1 scoop) + AND-16 Afternoon- PRP-02 (1 scoop) Night-PRP-02 (1 scoop) + FBR-18 (1 scoop) +PRO-19 II. Nutritional+ Behavioral counselling (Audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60-minute exercise 5 days a week or 150-300-minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)', 'armGroupLabels': ['Arm II (PRP-02 before all the meals)']}, {'name': 'Arm III', 'type': 'DIETARY_SUPPLEMENT', 'description': 'I. Investigational Product - Replace breakfast with BDK-01+PRP-02 (2 scoops) Afternoon - as per diet plan Night- FBR- 18 (1 scoop) +PRO- 19 II. Nutritional + Behavioral counselling (Daily audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60 minute exercise 5 days a week or 150 - 300 minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)', 'armGroupLabels': ['Arm III (1 meal replacement)']}, {'name': 'Arm IV', 'type': 'DIETARY_SUPPLEMENT', 'description': 'I. Investigational Product Replace breakfast with BDK-01+PRP-02 (2 scoops) Afternoon-BDK-01+ Skimmed milk powder (Only during intensive phase, in maintenance phase switch to 1 meal replacement only) Night-FBR- 18+PRO- 19 II. Nutritional + Behavioral counselling (Daily audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60 minute exercise 5 days a week or 150-300 minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)', 'armGroupLabels': ['Arm IV (2 Meal replacement)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '560090', 'city': 'Bangalore', 'state': 'Karnataka', 'country': 'India', 'facility': 'Sapthagiri Institute of Medical Sciences & Research Centre', 'geoPoint': {'lat': 12.97194, 'lon': 77.59369}}], 'overallOfficials': [{'name': 'Divya Divya', 'role': 'STUDY_DIRECTOR', 'affiliation': 'BioAgile Therapeutics Private Limited'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Bioagile Therapeutics Pvt. Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}